Pharmaceutical company Collegium Pharmaceutical (NASDAQ: COLL) will be reporting earnings tomorrow after market close. Here’s what to look for.
Collegium Pharmaceutical beat analysts’ revenue expectations by 1% last quarter, reporting revenues of $181.9 million, up 21.5% year on year. It was a strong quarter for the company, with a solid beat of analysts’ EPS estimates and full-year revenue guidance meeting analysts’ expectations.
Is Collegium Pharmaceutical a buy or sell going into earnings? Read our full analysis here, it’s free.
This quarter, analysts are expecting Collegium Pharmaceutical’s revenue to grow 19.2% year on year to $172.8 million, improving from its flat revenue in the same quarter last year. Adjusted earnings are expected to come in at $1.45 per share.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Collegium Pharmaceutical has missed Wall Street’s revenue estimates four times over the last two years.
Looking at Collegium Pharmaceutical’s peers in the branded pharmaceuticals segment, some have already reported their Q1 results, giving us a hint as to what we can expect. Bristol-Myers Squibb’s revenues decreased 5.6% year on year, beating analysts’ expectations by 3.9%, and Supernus Pharmaceuticals reported revenues up 4.3%, topping estimates by 1.3%. Bristol-Myers Squibb traded down 1.3% following the results.
Read our full analysis of Bristol-Myers Squibb’s results here and Supernus Pharmaceuticals’s results here.
There has been positive sentiment among investors in the branded pharmaceuticals segment, with share prices up 5.9% on average over the last month. Collegium Pharmaceutical is up 10% during the same time and is heading into earnings with an average analyst price target of $42.80 (compared to the current share price of $27.95).
When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we’ve found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback.
